Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Isoquercetin plus Aspirin

PreclinicalSmall molecule

UUniversity of Reading

Isoquercetin plus Aspirin is one of 2 small molecule programs targeting Platelet Function. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platelet FunctionWithdrawn

Platelet FunctionPreclinical

Withdrawn

Competition

Competitive Landscape

2 competitors in Platelet Function

#DrugCompanyPhaseTrials

Isoquercetin

JJeffrey Zwicker, MD

Isoquercetin plus Aspirin

UUniversity of Reading

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Platelet Function1 trial

Impact of isoQUercetin and Aspirin on Platelet Function

Withdrawn·UUniversity of Reading·N/A·NCT02866448

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isoquercetin plus Aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isoquercetin plus Aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isoquercetin plus Aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Reading company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Reading

Related News